Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
study ends around
Principal Investigator
by Jay Lee (ucla)Cathleen Park (uci)

Description

Summary

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Official Title

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

Keywords

Carcinoma, Non-Small-Cell Lung, Non-Small-Cell Lung Carcinoma, Pembrolizumab, Durvalumab, Olomorasib, Olomorasib + Pembrolizumab, Olomorasib + Durvalumab

Eligibility

Locations

Lead Scientists at University of California Health

  • Jay Lee (ucla)
    Associate Professor, Surgery, Medicine. Authored (or co-authored) 62 research publications
  • Cathleen Park (uci)
    Assistant Health Sciences Professor, Medicine, School of Medicine

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)
ID
NCT06890598
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 700 study participants
Last Updated